Bioengineering
Gynecologic oncology faces therapeutic stagnation, especially in high-grade serous carcinoma (HGSC), the deadliest ovarian cancer subtype [1]. PARP inhibitors (olaparib) show efficacy in homologous recombination-deficient tumors but are limited by systemic toxicity and development of acquired resistance. To expand therapeutic options and minimize toxicity, we developed macrophage-bound photocrosslinkable poly(β-amino ester) (PBAE) particle backpacks (BP) loaded with olaparib [2,3], enhancing delivery to the tumor microenvironment (TME) and reducing systemic exposures.
Courtney Bailey, MSc
PhD Student
University of Colorado, Colorado, United States